From the Guidelines
Silodosin is not recommended for use in females due to its specific indication for prostate-related urinary issues in men and lack of substantial clinical evidence supporting its efficacy for female urinary tract conditions. The medication is primarily approved and prescribed for men with benign prostatic hyperplasia (BPH) to improve urinary symptoms, as stated in the AUA guideline for the management of lower urinary tract symptoms attributed to BPH 1. While silodosin is an alpha-1 adrenergic receptor antagonist that can relax smooth muscle in the urinary tract, its use is tailored to prostate-related urinary issues in men.
The typical dose for men is 8 mg once daily, but this is not applicable to female patients. For women experiencing urinary symptoms, other medications such as mirabegron, oxybutynin, or tolterodine are more commonly prescribed, as these target the bladder specifically. Key considerations in the management of urinary symptoms in women include:
- The specific anatomy and physiology of the female urinary tract
- The lack of clinical evidence supporting the use of silodosin in women
- The potential side effects of silodosin, which are not relevant to female patients, such as abnormal ejaculation in men, as noted in the guideline 1.
If a woman is considering medication for urinary symptoms, she should consult with a healthcare provider to discuss more appropriate treatment options tailored to female urinary tract anatomy and physiology. The AUA guideline provides recommendations for the medical management of LUTS/BPH in men, but it does not address the use of silodosin in women 1. Therefore, alternative treatment options should be explored, prioritizing the patient's quality of life, morbidity, and mortality.
From the FDA Drug Label
Silodosin is not indicated for use in females.
8.1 Pregnancy Risk Summary Silodosin is not indicated for use in females.
8.2 Lactation Silodosin is not indicated for use in females.
The use of Silodosin in females is not indicated. 2 2
From the Research
Use of Silodosin in Females
There are no research papers to assist in answering this question, as all the provided studies focus on the use of silodosin in males, specifically for the treatment of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS) associated with BPH 3, 4, 5, 6, 7.
Key Points
- Silodosin is a highly selective α1A-adrenoceptor antagonist used to treat LUTS associated with BPH in men 3, 4, 5, 6, 7.
- The studies provided do not mention the use of silodosin in females.
- The efficacy and safety of silodosin have been demonstrated in several clinical trials, but these trials were conducted in male populations 3, 4, 5, 6, 7.